LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Kodu・Aktsiate loetelu・Alkermes PLC

Alkermes PLC

Suletud

SektorTervishoid

43.37 1.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.68

Max

44.5

Põhinäitajad
By Trading Economics
Sissetulek	-116M -66M
Müük	8.4M 393M
P/E Sektori keskmine	46.967 49.888
Aktsiakasum	0.38
Kasumimarginaal	-16.92
Töötajad	2,050
EBITDA	-98M -22M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+10.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	28. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	1.4B 7B
Eelmine avamishind	41.92
Eelmine sulgemishind	43.37

Uudiste sentiment

By Acuity

34%

66%

88 / 344 Pingereas Healthcare

Alkermes PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 12:22 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Pharma Sector Becoming Bidding Battlefield -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Alkermes PLC Prognoos

Hinnasiht

By TipRanks

10.89% tõus

12 kuu keskmine prognoos

Keskmine 45.82 USD 10.89%

Kõrge 53 USD

Madal 42 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Alkermes PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Alkermes PLC aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

88 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.